Enanta Pharmaceuticals Inc (ENTA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $320.09M
Last updated: Nov 17, 2026 at 11:05 AM ET
Enanta Pharmaceuticals Inc (ENTA) Stock Forecast
Analysts expect Enanta Pharmaceuticals (ENTA) to earn -$2.37 per share in the fiscal year ending Sep 30, 2027, on revenue of $63.74M. Of 6 analysts, 6 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Sep 30, 2027 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 1.83, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 16.7% |
| Buy | 5 | 83.3% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 6
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
- Fiscal year ending Sep 30, 2027
- -$2.37
- EPS consensus, revenue $63.74M
- Next report
- Feb 8, 2027
- Estimated
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Sep 30, 2027 | -$2.37 | -$3.08 to -$1.75 | 5 | $63.74M | $53.19M to $77.00M | 5 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.41 | -$0.48 to -$0.33 | 2 | $16.25M | $14.50M to $18.00M | 2 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 0 upward and 3 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Sep 30, 2027 | 0 | 2 |
| Quarter ending Dec 31, 2026 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Sep 30, 2027 has worsened from -$1.98.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Sep 30, 2027 | -$2.37 | -$2.37 | -$2.37 | -$2.07 | -$1.98 | N/A |
| Quarter ending Dec 31, 2026 | -$0.41 | -$0.37 | -$0.37 | -$0.37 | -$0.37 | N/A |
Frequently Asked Questions About ENTA
What is the ENTA stock forecast?
Consensus analyst estimates put Enanta Pharmaceuticals's EPS at -$2.37 for the fiscal year ending Sep 30, 2027, on revenue of $63.74M. The consensus rating from 6 analysts is Buy.
How do analysts rate ENTA stock?
Of 6 analysts covering Enanta Pharmaceuticals, 1 rates it Strong Buy, 5 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ENTA next year?
For the fiscal year ending Sep 30, 2027, the consensus EPS estimate is -$2.37, with estimates from -$3.08 to -$1.75 from 5 analysts.
What revenue do analysts expect from Enanta Pharmaceuticals next year?
For the fiscal year ending Sep 30, 2027, the consensus revenue estimate is $63.74M, with estimates from $53.19M to $77.00M.
How many analysts cover ENTA?
6 analysts rate Enanta Pharmaceuticals stock, and 5 analysts estimate its EPS for the fiscal year ending Sep 30, 2027.
ENTA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors